🔴 Lantern Pharma is trading 10.26% down in pre-market; no clear company-specific catalyst

Lantern Pharma is trading 10.26% down at $2.10 in pre-market, with no fresh company-specific announcement clearly explaining the decline.

• The latest identifiable catalyst was the August 14 second-quarter report, which included a $7.1 million net loss and $7.4 million in cash.
• That report is not sufficiently current to establish causation for the August 24, 2026 decline.
• Broader futures are modestly weaker, but the market signal is limited.